首页> 美国卫生研究院文献>Annals of Translational Medicine >Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?
【2h】

Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?

机译:多灶性肝细胞癌:肝内转移还是多中心癌变?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multifocal Hepatocellular carcinoma (HCC) may be multiple HCCs of multicentric origin (MO) or intrahepatic metastases (IM) arising from a primary HCC. Numerous attempts to differentiate the two types of multifocal HCC have been made including the valuation of the clinicopathologic characteristics of MO and IM patients and the recurrence time, loss-of-heterozygosity analysis of specific DNA microsatellite loci to distinguish multiclonal MO from IM of monoclonal origin, and the research of diagnostic and progression markers through genomic and proteomic analyses. These approaches, however, have been unsatisfactory hitherto. Recently, a multi-omic analysis of HBV-related multifocal HCCs, including intergraded genomics and transcriptomics, was performed and the results, validated by a cohort of 174 HCC patients, were correlated with HCC clinicopathological data. The two multifocal HCC types were effectively discerned by multi-omics profiling that could predict HCC clonality and aggressiveness. Further, the dual-specificity protein kinase TTK was recognized as a prognostic marker for HCC. Multi-omics strategy potentially opens new perspectives for the diagnosis, prognosis and personalized treatment of multi-focal HCC. Further work aimed at extending this strategy to HCC with other etiology, simplifying the analysis, and reducing its costs is necessary for its routine clinical application.
机译:多灶性肝细胞癌(HCC)可能是原发性HCC引起的多中心起源(MO)或肝内转移(IM)的多个HCC。已经做出了许多尝试来区分两种类型的多灶性肝癌,包括评估MO和IM患者的临床病理特征以及复发时间,特定DNA微卫星基因座的杂合丧失分析以区分多克隆MO与单克隆IM ,以及通过基因组和蛋白质组分析对诊断和进展标志物的研究。然而,迄今为止,这些方法并不令人满意。最近,对HBV相关的多灶性HCC进行了多组学分析,包括分级的基因组学和转录组学,该结果经174名HCC患者的队列验证,与HCC临床病理数据相关。可以通过预测HCC克隆性和侵略性的多组学分析有效区分了两种多灶性HCC类型。此外,双特异性蛋白激酶TTK被认为是HCC的预后标志物。多组学策略可能为多灶性肝癌的诊断,预后和个性化治疗开辟新的前景。进一步的工作旨在将该策略与其他病因一起扩展到HCC,简化分析并降低其成本,对于其常规临床应用而言是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号